LOS ANGELES, July 18, 2019 /PRNewswire-PRWeb/ -- Cannabinoid Biosciences ("CBDZ"), the Los Angeles-based biopharmaceutical company seeking to revolutionize and standardize pharmaceutical and non-pharmaceutical cannabidiol (CBD) products across the CBD market in the United States in particular and to some extent, the world, is set to launch its crowdfunding campaign to raise $50 million on August 5, 2019.
Established on May 6, 2014, Cannabinoid Biosciences ("CBDZ") is interested in the discovery, development, and commercialization of plant-derived cannabis products. In December 2018, the company filed a Regulation A+ with the U.S. Securities and Exchange Commission (SEC). In the same month, it added a CBD/THC scientist to its team to act as the Chief Scientific Officer in a deal that required the scientist to transfer all his previous inventions, including CBD-based formulations, to CBDZ.
On April 16, 2019, the SEC approved CBDZ's Regulation A+ Tier 2 Offering Circular filing, thereby fully enabling it to proceed with its crowdfunding campaign. Through the campaign, it seeks to raise $50 million from both accredited and non-accredited investors to purchase 10 dispensaries in a planned multi-state roll-up arrangement. In December 2018, the company initiated negotiation talks with the largest Indian reservation in Portland, Oregon to purchase a large expanse of land to grow cannabis and open a dispensary.
Furthermore, in its commitment to becoming Nasdaq-listed within 36 months, CBDZ initiated a detailed process of reviewing Stock Transfer Agents. On June 24, 2019, it finally selected one. The stock transfer agent will be in charge of keeping records of shareholders and their shares.
It is important to note that Cannabinoid Biosciences ("CBDZ") has been committed to making cannabis investing available to everyone. With just $100, through the investment fund, you can become an owner of nine shares in the company before it lists on an exchange. If it succeeds in its bid to get listed, your investment could significantly benefit from capital appreciation.
For instance, compared to its already-listed peers, CBDZ could generate up to $54 million and $17 million in revenue and profitability respectively and could consequently earn a market valuation north of $7.1 billion and south of $2.2 billion.
The pre-IPO investing will enable investors to easily get in the ground floor of cannabis investing, with the CBDZ's offering of market valuation to revenue of $2 to $1, which is far below the industry average. At the current average market cap to revenue of $131 to $1, investing in the industry has become expensive. As a result, CBDZ's offering is indeed a bargain, and small investors especially are expected to find it highly attractive.
So far, the company has enjoyed a significant measure of pre-launching success in its fundraising endeavor. Notably, on June 25, 2019, it announced it had been able to raise over $4.6 million, with at least 178 of the investors putting in between $1,000 to $5,000, 6 being investment funds, and 12 corporate entities.
About Cannabinoid Biosciences Inc.
Cannabinoid Biosciences, Inc., ("CBDZ") is a biopharmaceutical company with interests in the discovery, development, and commercialization of medical cannabis products.
CBDZ's mission is to revolutionize and standardize the pharmaceuticals and non-pharmaceutical CBD products across the CBD market in the United States of America and to some extent, globally. CBDZ seeks to control the production and distribution of verities of consumer cannabidiol (CBD) formulation under private brands in the United States. CBDZ's goal is to bring standardization to the CBD industry, the same way that John D Rockefeller's Standard Oil brought standardization to crude refining in the United States in the nineteenth century.
CBDZ is also seeking interest and control interest in the discovery, development, and commercialization of novel drugs using different cannabis products ?proprietary cannabinoid, cannabidiol, endocannabinoids, phytocannabinoids, and synthetic cannabinoid products. Its operating strategy is research and development and pipeline acquisition. The company's aim using this approach, is to develop quality plant-derived cannabinoid therapeutic products for specific medical conditions and diseases and to commercialise them through collaborations with pharmaceutical companies. Notably, the strategy has already resulted in GW Pharmerceutical's production of the first cannabis plant-derived medicine ever approved by the FDA, Epidiolex®, a cannabidiol-based formulation for seizures associated with two forms of drug-resistant epilepsy syndromes.
CBDZ's product lineup includes tinctures, capsules, gummies, bath bombs, vape oils, topical creams, and animal treats and oils. The company will sell its products directly to consumers through the company Website, as well as non-affiliated stores in about 40 states. The company was founded in 2014 and is based in Los Angeles, California. https://cbdxfund.com/invest/
The global cannabis industry has been witnessing tremendous growth in recent years. In 2018 alone, global cannabis sales hit $12.2 billion, with an expectation of over 30% growth for 2019. The use of medical cannabis has been given the green light in 33 states while 10 states have also legalized its recreational use. The Californian cannabis industry alone is expected to be worth $6.6 billion by 2020. By the same year, the total US-based market might have as well increased to $23 billion ? from just the $3.4 billion valuation in 2015.
However, there is a problem. For someone seeking a bargain, getting in on the ground floor of cannabis investment has become prohibitively expensive. This fact can be perfectly illustrated with the $1.8 billion deal whereby Altria, the Marlboro cigarette manufacturer, paid $250 per 1$ of Cronos' revenue to acquire a 45% stake in the Canadian cannabis company which generated only $16 million in annual revenue in its most recent fiscal year. Also, the current average market capitalization to revenue of $131 per $1 for publicly traded cannabis businesses makes it almost impossible to find bargain deals in the cannabis investment space.
Then, enters CBDZ:
Cannabinoid Biosciences, Inc. ("CBDZ"): Aims to make CBD/Cannabis Investment More Accessible to the general public at the ground level.
As a result of the currently high barriers, there is a need for the provision of bargain cannabis investment deals for ordinary investors. Cannabinoid Biosciences ("CBDZ") is currently meeting that need. Driven by the belief that cannabis should be an open investment opportunity for all, the company has proposed a stock offering of 5,000,000 shares available to anyone, accredited or non-accredited investors ? and even to those who do not have a stock brokerage account!
At $10 per share, for as little as $100, you can become an owner of nine shares of the company, the minimum investment plan it offers, before it finally lists on an exchange. Hence, with the offering, you would be purchasing licensed cannabis businesses at less than $2 in market cap for every $1 of revenue generated, which is far below the industry average. As spelled out in its Reg A + filing, the company plans to use the expected $50 million crowdfunded funds to purchase 10 dispensaries with cultivation licenses in a multi-state rollup.
CBDZ's plan is to list on a major Canadian or US-based exchange such as CSE, NYSE, or Nasdaq. After its public listing, compared to the current NASDAQ/NYSE listed pool of Cannabis companies, CBDZ can ultimately have as much as $54 million in revenue. Also, it can attain a robust profitability of $17 million. Most exciting is the prospect that the company's valuation can be as high as $7.1 billion after the listing.
Frank Igwealor, Sr. Vice President and CFO
Cannabinoid Biosciences, Inc.
Visit us on social media:
SOURCE Cannabinoid Biosciences
These press releases may also interest you